SG11201911814UA - Anti-trkb antibodies - Google Patents
Anti-trkb antibodiesInfo
- Publication number
- SG11201911814UA SG11201911814UA SG11201911814UA SG11201911814UA SG11201911814UA SG 11201911814U A SG11201911814U A SG 11201911814UA SG 11201911814U A SG11201911814U A SG 11201911814UA SG 11201911814U A SG11201911814U A SG 11201911814UA SG 11201911814U A SG11201911814U A SG 11201911814UA
- Authority
- SG
- Singapore
- Prior art keywords
- trkb antibodies
- trkb
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17175122 | 2017-06-09 | ||
PCT/EP2018/065107 WO2018224630A1 (en) | 2017-06-09 | 2018-06-08 | Anti-trkb antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201911814UA true SG11201911814UA (en) | 2020-01-30 |
Family
ID=59034551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201911814UA SG11201911814UA (en) | 2017-06-09 | 2018-06-08 | Anti-trkb antibodies |
Country Status (22)
Country | Link |
---|---|
US (3) | US10793634B2 (en) |
EP (1) | EP3635004A1 (en) |
JP (2) | JP7267208B2 (en) |
KR (1) | KR20200017421A (en) |
CN (1) | CN110719916B (en) |
AR (1) | AR112602A1 (en) |
AU (1) | AU2018279184B2 (en) |
BR (1) | BR112019023742A2 (en) |
CA (1) | CA3063965A1 (en) |
CL (1) | CL2019003557A1 (en) |
CO (1) | CO2019013718A2 (en) |
EA (1) | EA201992883A1 (en) |
IL (1) | IL271067B2 (en) |
MA (1) | MA49257A (en) |
MX (1) | MX2019014714A (en) |
MY (1) | MY202315A (en) |
PE (1) | PE20200173A1 (en) |
PH (1) | PH12019502694A1 (en) |
SG (1) | SG11201911814UA (en) |
TW (2) | TW202342100A (en) |
UA (1) | UA127967C2 (en) |
WO (1) | WO2018224630A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019022074A2 (en) * | 2017-06-02 | 2020-05-12 | Boehringer Ingelheim International Gmbh | ANTICANCER COMBINATION THERAPY |
CA3156452A1 (en) | 2019-11-11 | 2021-05-20 | Boehringer Ingelheim International Gmbh | Npy2 receptor agonists |
US20220119536A1 (en) * | 2020-10-21 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Agonistic trkb binding molecules for the treatment of eye diseases |
WO2023125485A1 (en) * | 2021-12-28 | 2023-07-06 | 4B Technologies (Beijing) Co., Limited | TrkB ANTIBODY AND APPLICATION THEREOF |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
JPS6023084B2 (en) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | blood substitute |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (en) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Process for the biotechnical production of alkaline phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
DE68925971T2 (en) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF PRODUCTS |
FR2646437B1 (en) | 1989-04-28 | 1991-08-30 | Transgene Sa | NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DK0590058T3 (en) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humanized heregulin antibody |
DK0669836T3 (en) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Therapeutic use of chimeric and radiolabeled antibodies and human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
CN101273064A (en) | 2005-06-06 | 2008-09-24 | 惠氏公司 | Anti-TrkB monoclonal antibodies and uses thereof |
CA2669205A1 (en) * | 2006-11-09 | 2008-05-15 | Irm Llc | Agonist trkb antibodies and uses thereof |
JP2010513461A (en) | 2006-12-20 | 2010-04-30 | ライナット ニューロサイエンス コーポレイション | TrkB agonists for treating autoimmune disorders |
JP5674469B2 (en) | 2007-10-11 | 2015-02-25 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Method of treating pressure-induced optic neuropathy through administration of a LINGO-1 antagonist and a TrkB agonist, preventing neurodegeneration and promoting neuronal cell survival |
CA2703329A1 (en) | 2007-10-23 | 2009-04-30 | Novartis Ag | Use of trkb antibodies for the treatment of respiratory disorders |
EA028621B1 (en) * | 2008-01-17 | 2017-12-29 | Новартис Аг | ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT THEREOF THAT SPECIFICALLY BIND TYROSINE RECEPTOR KINASE (TrkB), PHARMACEUTICAL COMPOSITION COMPRISING THIS ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT THEREOF, AND COMBINATION COMPRISING SAID COMPOSITION |
PT2252633E (en) * | 2008-02-04 | 2013-11-19 | Lay Line Genomics Spa | Anti-trka antibodies and derivatives thereof |
CA2732266A1 (en) | 2008-07-28 | 2010-02-04 | Emory University | Treating various disorders using trkb agonists |
WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
WO2011103667A1 (en) | 2010-02-26 | 2011-09-01 | 6452728 Canada Inc. | Agonistic antibodies to trkb receptors and uses thereof |
US9029561B2 (en) | 2010-06-09 | 2015-05-12 | Emory University | TRKB agonists and methods of use |
WO2012027821A1 (en) | 2010-09-03 | 2012-03-08 | The Royal Institution For The Advancement Of Learning / Mcgill University | A trkc receptor agonist antibody to treat neurodegenerative and motor neuron diseases |
GB2491106A (en) | 2011-05-18 | 2012-11-28 | Univ Basel | Antibodies against tropomyosin-related kinase B receptors |
US10392438B2 (en) | 2014-05-16 | 2019-08-27 | Pfizer Inc. | Bispecific antibodies |
BR112018001900A2 (en) | 2015-07-28 | 2018-09-18 | Otonomy, Inc. | trkb or trkc agonist compositions and methods for treating optical conditions |
TW201730206A (en) | 2015-11-17 | 2017-09-01 | 葛蘭素史克智慧財產發展有限公司 | Binding agonists for treatment of neurological and other disorders |
CA3083452A1 (en) | 2017-11-30 | 2019-06-06 | Regeneron Pharmaceuticals, Inc. | Anti-trkb monoclonal antibodies and methods of use |
-
2018
- 2018-06-07 US US16/002,058 patent/US10793634B2/en active Active
- 2018-06-08 WO PCT/EP2018/065107 patent/WO2018224630A1/en active Application Filing
- 2018-06-08 SG SG11201911814UA patent/SG11201911814UA/en unknown
- 2018-06-08 AR ARP180101558 patent/AR112602A1/en unknown
- 2018-06-08 EA EA201992883A patent/EA201992883A1/en unknown
- 2018-06-08 PE PE2019002525A patent/PE20200173A1/en unknown
- 2018-06-08 JP JP2019567701A patent/JP7267208B2/en active Active
- 2018-06-08 EP EP18731764.9A patent/EP3635004A1/en active Pending
- 2018-06-08 MY MYPI2019007297A patent/MY202315A/en unknown
- 2018-06-08 KR KR1020197037817A patent/KR20200017421A/en active Search and Examination
- 2018-06-08 MA MA049257A patent/MA49257A/en unknown
- 2018-06-08 IL IL271067A patent/IL271067B2/en unknown
- 2018-06-08 TW TW112123529A patent/TW202342100A/en unknown
- 2018-06-08 BR BR112019023742A patent/BR112019023742A2/en unknown
- 2018-06-08 UA UAA201911908A patent/UA127967C2/en unknown
- 2018-06-08 CA CA3063965A patent/CA3063965A1/en active Pending
- 2018-06-08 MX MX2019014714A patent/MX2019014714A/en unknown
- 2018-06-08 AU AU2018279184A patent/AU2018279184B2/en active Active
- 2018-06-08 TW TW107119755A patent/TWI808086B/en active
- 2018-06-08 CN CN201880038098.6A patent/CN110719916B/en active Active
-
2019
- 2019-11-28 PH PH12019502694A patent/PH12019502694A1/en unknown
- 2019-12-05 CO CONC2019/0013718A patent/CO2019013718A2/en unknown
- 2019-12-05 CL CL2019003557A patent/CL2019003557A1/en unknown
-
2020
- 2020-08-26 US US17/002,907 patent/US11866501B2/en active Active
-
2023
- 2023-04-19 JP JP2023068735A patent/JP7505084B2/en active Active
- 2023-11-28 US US18/520,650 patent/US20240101689A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL268517A (en) | Anti-tigit antibodies | |
IL272227A (en) | Anti-tigit antibodies | |
ZA201905966B (en) | Anti-lag3 antibodies | |
PL3625259T3 (en) | Anti-sirpalpha antibodies | |
IL267797B1 (en) | Anti-gpc3 antibody | |
GB201709808D0 (en) | Antibodies | |
GB201601073D0 (en) | Antibodies | |
IL273393A (en) | Novel anti-cd3epsilon antibodies | |
SG10201914130VA (en) | GARP-TGF-β ANTIBODIES | |
ZA202002141B (en) | Anti-transthyretin antibodies | |
GB201610044D0 (en) | Antibodies | |
GB201603291D0 (en) | Antibodies | |
GB201720970D0 (en) | Antibodies | |
ZA202103456B (en) | Anti-alpha-synuclein antibodies | |
IL271067A (en) | Anti-trkb antibodies | |
IL273529A (en) | Anti-pacap antibody | |
GB201711785D0 (en) | Antibodies | |
GB201717006D0 (en) | Anti-OPG antibodies | |
GB201709818D0 (en) | Antibodies | |
GB201703071D0 (en) | Antibodies | |
GB201701416D0 (en) | Anti-OPG antibodies | |
GB201709592D0 (en) | Antibody |